Literature DB >> 15996249

Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation.

B Fellström1, A G Jardine, I Soveri, E Cole, H-H Neumayer, B Maes, C Gimpelewicz, H Holdaas.   

Abstract

Renal transplant recipients (RTR) have shortened life expectancy, primarily due to premature cardiovascular disease (CVD). Traditional CVD risk factors are highly prevalent. In addition, several non-traditional risk factors may contribute to the high risk. The aim of the study was to evaluate the effects of renal dysfunction on mortality and cardiovascular complications in 1052 placebo-treated patients of the Assessment of LEscol in Renal Transplantation (ALERT) trial. Follow-up was 5-6 years and endpoints included cardiac death, non-cardiovascular death, all-cause mortality, major adverse cardiac event (MACE), non-fatal myocardial infarction (MI) and stroke. The effects of serum creatinine at baseline on these endpoints were evaluated. Elevated serum creatinine in RTR was a strong and independent risk factor for MACE, cardiac, non-cardiovascular, and all-cause mortality, but not for stroke or non-fatal MI alone. Serum creatinine was associated with increased mortality and MACE, independent of established CVD risk factors. Graft loss resulted in increased incidences of non-cardiovascular death, all-cause mortality, MACE and non-fatal MI. In conclusion, elevated serum creatinine is a strong risk factor for all-cause, non-cardiovascular and cardiac mortality, and MACE, independent of traditional risk factors, but not for stroke or non-fatal MI alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996249     DOI: 10.1111/j.1600-6143.2005.00983.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  17 in total

1.  Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.

Authors:  D E Weiner; M A Carpenter; A S Levey; A Ivanova; E H Cole; L Hunsicker; B L Kasiske; S J Kim; J W Kusek; A G Bostom
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

2.  Impaired renal function is associated with mortality in kidney-transplanted patients.

Authors:  Adam Remport; Miklos Zsolt Molnar; Csaba Ambrus; Andras Keszei; Szilard Torok; Eszter Panna Vamos; Istvan Kiss; Jeno Jaray; Marta Novak; Laszlo Rosivall; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-09-25       Impact factor: 2.370

Review 3.  Estimating glomerular filtration rate in kidney transplantation: Still searching for the best marker.

Authors:  Josefina Santos; La Salete Martins
Journal:  World J Nephrol       Date:  2015-07-06

4.  Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.

Authors:  Jing Zhou; Lingfeng Qin; Tai Yi; Rahmat Ali; Qingle Li; Yang Jiao; Guangxin Li; Zuzana Tobiasova; Yan Huang; Jiasheng Zhang; James J Yun; Mehran M Sadeghi; Frank J Giordano; Jordan S Pober; George Tellides
Journal:  Circ Res       Date:  2015-09-23       Impact factor: 17.367

5.  Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience.

Authors:  Sameer M Alarrayed; Amgad E El-Agroudy; Ahmad S Alarrayed; Sumaya M Al Ghareeb; Taysir S Garadah; Salah Y El-Sharqawi; Ali H Al-Aradi; Balaji G Dandi; Sadiq Abdulla
Journal:  Clin Exp Nephrol       Date:  2010-03-16       Impact factor: 2.801

6.  A kidney offer acceptance decision tool to inform the decision to accept an offer or wait for a better kidney.

Authors:  Andrew Wey; Nicholas Salkowski; Walter K Kremers; Cory R Schaffhausen; Bertram L Kasiske; Ajay K Israni; Jon J Snyder
Journal:  Am J Transplant       Date:  2017-10-17       Impact factor: 8.086

Review 7.  Steroids in kidney transplant patients.

Authors:  Robert W Steiner; Linda Awdishu
Journal:  Semin Immunopathol       Date:  2011-02-18       Impact factor: 9.623

Review 8.  Cardiovascular disease in patients with chronic kidney disease.

Authors:  Julian Wright; Alastair Hutchison
Journal:  Vasc Health Risk Manag       Date:  2009-09-07

Review 9.  HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Authors:  Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; Vlado Perkovic; David W Johnson; Sagar U Nigwekar; Jorgen Hegbrant; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-01-28

Review 10.  Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients.

Authors:  J R Bank; T J Rabelink; J W de Fijter; M E J Reinders
Journal:  J Immunol Res       Date:  2015-07-15       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.